Any platform that approves prescriptions for patients with a BMI below 27 without documented comorbidities, or that skips intake review entirely and auto-approves all submissions, is operating outside accepted clinical standards
Tirzepatide is not for everyone
AOD9604 and Safety Pharmacology Research A conventional Ames test showed no significant mutation rate increase for AOD9604 at up to 2,000 g/plate, with no clastogenic effects observed in CHO-cell chromosome aberration assays
This article is not affiliated with, endorsed by, or sponsored by Novo Nordisk
The GLORY-2 trial tested the higher 9 mg dose
The low expression of GLP-1R across cancer types and the low frequency of genetic alterations suggest a limited direct role of GLP-1R mutations in cancer progression, but its variable expression may influence tumor behavior